Key result
DOAC Stop significantly removed the effects of rivaroxaban and apixaban on coagulation assays and reduced false positive lupus anticoagulant interpretations in patient samples.
Why the study?
DOACs interfere with clotting tests, and the authors sought to investigate whether DOAC Stop removes rivaroxaban and apixaban effects across haemostasis assays to enable more accurate interpretation.
Does DOAC Stop remove the interference of rivaroxaban and apixaban on coagulation assays in patient plasma samples?
Population
Plasma samples from patients anticoagulated with rivaroxaban, apixaban, or no anticoagulant
Comparison
Coagulation assay testing before vs after sample treatment with DOAC Stop
Design
In vitro laboratory study
Authors
Loading...
DOAC Stop mitigates rivaroxaban/apixaban interference in haemostasis assays; leaves open routine adoption pending prospective validation.
Does DOAC Stop remove the interference of rivaroxaban and apixaban on coagulation assays in patient plasma samples?
DOAC Stop effectively removes the interference of rivaroxaban and apixaban from plasma samples, enabling more accurate interpretation of coagulation assays such as lupus anticoagulant screening.
Platton et al. (2018) studied Patients on rivaroxaban or apixaban. DOAC Stop vs. Samples before treatment with DOAC-Stop was evaluated on Effect on coagulation assays (PT, APTT, anti-Xa, factor VIII, DRVVT). DOAC Stop significantly removed the effects of rivaroxaban and apixaban on coagulation assays and reduced false positive lupus anticoagulant interpretations in patient samples.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: